NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Attana AB
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Attana AB Introduces the Attana Cell 200 - Potentially Improves Drug Development - Attana Cell 200 – the first system to permit real-time kinetic analysis of molecular interactions directly on cell surfaces, bringing drug development a step closer to the body
Attana AB Introduces the Attana Cell 200 - Potentially Improves Drug Development

 

NewswireToday - /newswire/ - Stockholm, Sweden, 2010/02/01 - Attana Cell 200 – the first system to permit real-time kinetic analysis of molecular interactions directly on cell surfaces, bringing drug development a step closer to the body.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

As the first company in the world, Attana launches a system measuring molecular interactions label free directly on cell surfaces. In line with Attana’s innovative strategy, the Attana Cell 200 is a revolutionary system that rapidly generates biologically relevant information on molecular interactions with cell surfaces. Thanks to groundbreaking innovations and sedulous developments, Attana is the only player on the market that offers cells integrated as sensor surface. The experiments mimic real life conditions and generate information with higher biological relevance in comparison with traditional synthetic sensor surfaces.

Drug development is financially risky and time consuming. To save money and time the industry needs to early identify and eliminate unsuitable candidates. Attana Cell 200 biosensor system improves the selection process by rapidly identifying promising drug candidates. This enables early and well informed decisions in selecting relevant candidates while reducing unnecessary development costs and saving time. The Attana Cell 200 is label free, can run unpurified candidate molecules and has high throughput, resulting in fast and efficient screening of many drug candidates.

Attana Cell 200 is launched with new applications such as kinetic evaluation of cellular biomolecular interactions, e.g. antibody-receptor and lectin-carbohydrate, competition assays and cell capturing.

About Attana AB

Based in Stockholm, Sweden, Attana AB (attana.com) develops and sells biosensors for analysis of biomolecular interactions. Our systems have since 2003 been employed at leading life science companies and universities worldwide, working in a wide variety of research fields. Attana’s biosensors can be used to determine specificity, kinetics and affinity, amongst other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Attana AB

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Attana AB Introduces the Attana Cell 200 - Potentially Improves Drug Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Gabriela Suhoschi - Attana.com 
+46(0)8 674 57 12 gabriela.suhoschi[.]attana.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Attana AB securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Attana AB / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Global Natural History Study of Fibrodysplasia Ossificans Progressiva Shows Debilitating Impact of the Disease Over An Individual’s Lifetime
BASF and Evonik Partner to Reduce the Environmental Footprint of the Feed and Animal Protein Industries
Rely+On Virkon from LANXESS Effective Against Monkeypox Virus
DSM Completes Acquisition of Prodap
Bruker’s Arxspan Business for Lab Informatics Expands Customer Capabilities by Joining Tetra Partner Network
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-line Monotherapy for Small Cell Lung Cancer
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-oncology Candidates from Marengo’s STAR Platform
SCHOTT Establishes Stand-alone Company for its Pharma Business to Promote Further Growth
Bushu Pharma Lauded by Frost & Sullivan for Enabling the Launch of Specialty Drugs in Japan and Asia-Pacific
BASF Expands World-scale Vitamin A Formulation Plant in Ludwigshafen
Ipsen to Acquire Epizyme, Expanding its Portfolio in Oncology
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
GenScript ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults
DSM Acquires Brazil’s Leading Animal Nutrition Technology Company to Boost Precision Services Offering

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)